Company intelligence / Profile preview

Mercy House

Natick, MA, USA

Ownership: Private
Employees: ~45
Development stage: Other

Overview

Mercy BioAnalytics is a clinical-stage diagnostics company focused on the early detection of cancer using its proprietary Mercy Halo™ platform. The technology analyzes extracellular vesicles (EVs), which are shed by cancer cells into the bloodstream, to identify disease-specific biomarkers at the earliest stages. By combining high-sensitivity assays with machine learning, Mercy aims to provide non-invasive, accurate screening for high-incidence cancers such as lung and ovarian cancer. The company's mission is to transform cancer care by enabling early intervention when treatment is most effective.

Therapeutic areas: Oncology
Modalities: Liquid BiopsyExtracellular Vesicle AnalysisImmunoassay
Industry: Protein Biomarker Diagnostics

Partnerships

Mayo Clinic

Beyond the preview

Go deeper on Mercy House.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mercy House.

Explore the full profile